See more : E & M Computing Ltd. (EMCO.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Entrada Therapeutics, Inc. (TRDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Entrada Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hamama Meir Trading (1996) Ltd. (HMAM.TA) Income Statement Analysis – Financial Results
- Bridgemarq Real Estate Services Inc. (BREUF) Income Statement Analysis – Financial Results
- Healthwell Acquisition Corp. I (HWELU) Income Statement Analysis – Financial Results
- Dignity plc (DGNYF) Income Statement Analysis – Financial Results
- NS Tool Co., Ltd. (6157.T) Income Statement Analysis – Financial Results
Entrada Therapeutics, Inc. (TRDA)
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 129.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 99.88M | 1.90M | 1.12M | 326.00K | 104.00K |
| Gross Profit | 29.13M | -1.90M | -1.12M | -326.00K | -104.00K |
| Gross Profit Ratio | 22.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 99.88M | 66.61M | 35.93M | 21.10M | 8.22M |
| General & Administrative | 32.29M | 30.64M | 15.20M | 5.57M | 3.61M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.29M | 30.64M | 15.20M | 5.57M | 3.61M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 6.27M |
| Operating Expenses | 132.18M | 97.25M | 51.13M | 26.67M | 11.82M |
| Cost & Expenses | 132.18M | 97.25M | 51.13M | 26.67M | 11.82M |
| Interest Income | 15.22M | 2.63M | 0.00 | 144.00K | 451.00K |
| Interest Expense | 0.00 | 2.63M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.84M | 1.90M | 1.12M | 326.00K | 104.00K |
| EBITDA | -321.00K | -95.35M | -50.01M | -26.34M | -11.72M |
| EBITDA Ratio | -0.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.16M | -97.25M | -51.13M | -26.67M | -11.82M |
| Operating Income Ratio | -2.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.22M | 2.63M | -31.00K | 144.00K | 6.72M |
| Income Before Tax | 12.06M | -94.62M | -51.16M | -26.52M | -5.10M |
| Income Before Tax Ratio | 9.34% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 18.74M | -7.16M | -1.09M | -144.00K | -451.00K |
| Net Income | -6.69M | -87.46M | -50.07M | -26.38M | -4.65M |
| Net Income Ratio | -5.18% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.20 | -2.79 | -1.60 | -0.84 | -0.15 |
| EPS Diluted | -0.20 | -2.79 | -1.60 | -0.84 | -0.15 |
| Weighted Avg Shares Out | 33.05M | 31.29M | 31.22M | 31.25M | 31.25M |
| Weighted Avg Shares Out (Dil) | 33.05M | 31.29M | 31.22M | 31.25M | 31.25M |
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week Of 4/20
U.S. IPO Weekly Recap: Semiconductors And Energy Storage Lead A Spooky 14 IPO Week
GridGlo Recognized as one of Florida’s Most Promising Clean Tech Companies
The Florida Venture Forum Selects Judges for its Inaugural 2011 Statewide Collegiate Business Plan Competition
Source: https://incomestatements.info
Category: Stock Reports